BICO’s Annual General Meeting will be held on Thursday, May 8, 2025, at 4:00 p.m. at BICO’s daughter company CELLINK, Långfilsgatan 1, 412 77, Gothenburg, Sweden.   Registration for the Meeting will commence at 3:30 p.m The shareholders will also have

General Terms & Conditions of Purchase Learn more about the conditions that govern the sale of our products, including delivery, payment terms and warranties. Our General Terms & Conditions of Sale are applicable for all companies within the Group.

FRANKLIN LAKES, N.J. and SAN DIEGO (Jan. 23, 2025) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biosero, a developer of laboratory automation solutions to orchestrate scientific discoveries, today

2025 2024 2023 2022 2021 2020 2019 2018 Documents Annual General Meeting 8 May 2025 → Notice AGM Nomination Committee proposals and reasoned statement Proxy form Notification of attendance and form for advance voting Auditor’s report in accordance with

In accordance with the instruction for the Nomination committee adopted by the Annual General Meeting 2025, the Nomination Committee of BICO Group AB shall consist of four members appointed by the largest shareholders by the last day of September. The

Corporate Governance Report 2024 Corporate Governance Report 2023 Corporate Governance Report 2022 Corporate Governance Report 2021 Corporate Governance Report 2019/2020 Corporate Governance Report

Rolf Classon Chairman of the Board More info Born 1945. Board member since 2022. Chairman since 2023. Member of Audit Committee. Education and work experience:Chemical Engineer and Pol.Mag., from Gothenburg University. 40+ years experience in Pharmaceuticals,

Maria Forss President and CEO More info Born 1972. CEO since 2023. Education and work experience: M.Sc. in Business Administration from Gothenburg School of Economics & Concordia University, Montreal, Canada. Executive Management Program at Stanford

Reports Press releases Calendar Contact Q2 Report 2025 Read Report Webcast Earnings Call Presentation BICO Strategy 2.0 Watch Now Presentation Capital Markets Day 2024 BICO by Numbers Net Sales APRIL – JUNE 2025 280 M SEK Organic GrowthAPRIL –

All numbers on this page refers to Ginolis being classified as discontinued operations from the Q4 2023, Nanoscribe from Q4 2024 and Mattek and Visiokol from Q2 2025 with retroactive effect. * From Q1 2024, BICO has changed to functional reporting with